Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Zagotenemab · 1 trial · 1 indication
Integrated Alzheimer's Disease Rating Scale (iADRS) is a simple linear combination of scores from 13-item alzheimer's disease assessment scale-cognitive subscale (ADAS-Cog13) and the Alzheimer's disease cooperative study-instrumental activities of daily living scale (ADCS-iADL). It is used to assess whether zagotenemab slows down the cognitive and functional decline associated with early symptomatic Alzheimer's Disease, compared to placebo. The iADRS score ranges from 0 to 144 with lower scores indicating worse performance and higher score better performance. Change from baseline was calculated using Bayesian disease progression model (DPM) with fixed, categorical effects of treatment, pooled site, acetylcholinesterase inhibitor (AChEI) use at baseline (yes/no), and the continuous effects of baseline score and age at baseline. Data presented are posterior mean with 95% credible interval.
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Participants received intravenous (IV) infusion of placebo once every four weeks (Q4W) for 100 weeks. |
| Zagotenemab 1400 mg | EXPERIMENTAL | Participants received IV infusion of 1400 milligram (mg) zagotenemab Q4W for 100 weeks. |
| Zagotenemab 5600 mg | EXPERIMENTAL | Participants received IV infusion of 5600 mg zagotenemab Q4W for 100 weeks. |
| Name | Type | Description |
|---|---|---|
| Zagotenemab | DRUG | Administered IV |
| Placebo | DRUG | Administered IV |
Inclusion Criteria: * Participants must have gradual and progressive change in memory function for \>6 months. * Participants must have a family member or close friend who is with you at least 10 hours per week and can attend study appointments. Exclusion Criteria: * Participants must not have si...
Top 20 of 24 competitors
Zagotenemab is an investigational small molecule being studied for the treatment of early symptomatic Alzheimer's Disease (AD). It is being developed by Eli Lilly and Company and is currently in Phase 2 clinical development.
Zagotenemab is a small molecule being studied for Alzheimer's Disease. The specific molecular target of Zagotenemab has not been disclosed in the available information.
Zagotenemab is being developed by Eli Lilly and Company, a pharmaceutical company traded on the stock exchange under the ticker symbol LLY.
Zagotenemab is in Phase 2 clinical development for Alzheimer's Disease. It is an investigational drug and has not been approved by regulatory authorities.
Zagotenemab has one completed Phase 2 clinical trial, identified as NCT03518073, which studied the drug in participants with early symptomatic Alzheimer's Disease. The trial enrolled 360 participants and was conducted in the United States, Canada, and Japan.
Yes, Zagotenemab is also known as LY3303560. The clinical trial NCT03518073, which studied Zagotenemab, is titled 'A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease'.